Figure 1.
Subject disposition for the entire Genetic and Inflammatory Markers of Sepsis (GenIMS) cohort.
CAP indicates community-acquired pneumonia.
Table 1.
Demographic and clinical characteristics.
Table 2.
Mean, median, interquartile range, and percentage of subjects with abnormal hemostasis marker levels at hospital discharge.
Figure 2.
Varying hazard ratios with 95% confidence intervals (CI) for circulating thrombin-antithrombin (TAT) complexes, D-dimer, plasminogen activator inhibitor (PAI)-1, and interleukin (IL)-6 concentrations measured at hospital discharge and mortality over 1 year.
The hazard ratios are shown over ten time intervals based on the Grays' model. For TAT, D-dimer, and IL-6, the lower bounds of the CI are above 1 for the first 111 days. For PAI-1, the lower bounds of the 95% CI are above 1 for the first 44 days.
Figure 3.
Failure plots for high and low concentrations (25th and 75th percentiles of marker concentrations) of thrombin-antithrombin (TAT) complexes, D-dimer, plasminogen activator inhibitor (PAI)-1, and interleukin (IL)-6 concentrations measured at hospital discharge and mortality over 1 year.
Using the Gray's model, the hazard ratios are estimated at ten intervals over 1 year and hazard ratios over five representative periods are shown. P values are obtained from the Grays' survival model.
Table 3.
Hazard ratios* for association between circulating hemostasis markers at hospital discharge and all-cause mortality over 1 year.
Table 4.
Sensitivity analyses for association between circulating hemostasis marker concentrations at hospital discharge and mortality over 1 year.
Table 5.
Association between hemostasis markers at hospital discharge and cause-specific mortality over 1 year*.
Table 6.
Area under curve (AUC) to determine discriminative ability of interleukin (IL)-6 and D-dimer to predict long-term outcomes.